Pirtobrutinib
Details of the Drug
- Generic Name:
- Pirtobrutinib
- Drug Type:
- Non-covalent (reversible) BTK inhibitor (inhibitor that can be used even when a patient's cancer has become resistant to older BTK inhibitors)
- How the Drug is Given:
Orally
- Names:
- Pirtobrutinib
- Jaypirca®
Indications and Usage
Pirtobrutinib is indicated for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Side effects needing medical attention
Most common adverse reactions are fatigue, musculoskeletal pain, diarrhea, COVID-19, bruising, and cough. The most common laboratory abnormalities are neutrophil count decreased, platelet count decreased, hemoglobin decreased, and lymphocyte count decreased.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.